2.09
price down icon0.48%   -0.01
after-market アフターアワーズ: 2.10 0.01 +0.48%
loading
前日終値:
$2.10
開ける:
$2.12
24時間の取引高:
4.37M
Relative Volume:
0.57
時価総額:
$722.08M
収益:
$22,000
当期純損益:
$-173.76M
株価収益率:
-2.721
EPS:
-0.7681
ネットキャッシュフロー:
$-109.53M
1週間 パフォーマンス:
+1.95%
1か月 パフォーマンス:
+12.97%
6か月 パフォーマンス:
+1.95%
1年 パフォーマンス:
+86.61%
1日の値動き範囲:
Value
$2.06
$2.15
1週間の範囲:
Value
$2.00
$2.23
52週間の値動き範囲:
Value
$1.04
$4.46

Allogene Therapeutics Inc Stock (ALLO) Company Profile

Name
名前
Allogene Therapeutics Inc
Name
セクター
Healthcare (1080)
Name
電話
(650) 457-2700
Name
住所
210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO
Name
職員
152
Name
Twitter
@AllogeneTx
Name
次回の収益日
2026-08-12
Name
最新のSEC提出書
Name
ALLO's Discussions on Twitter

Compare ALLO vs VRTX, REGN, ARGX, MRNA, RVMD

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
ALLO icon
ALLO
Allogene Therapeutics Inc
2.09 725.53M 22,000 -173.76M -109.53M -0.7681
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
548.05 136.93B 12.34B 4.34B 3.71B 16.87
REGN icon
REGN
Regeneron Pharmaceuticals Inc
834.04 85.11B 14.92B 4.42B 3.79B 41.04
ARGX icon
ARGX
Argen X Se Adr
1,039.78 64.95B 4.16B 1.29B 734.26M 19.58
MRNA icon
MRNA
Moderna Inc
145.13 53.23B 2.23B -3.19B -1.60B -8.1462
RVMD icon
RVMD
Revolution Medicines Inc
209.46 45.38B 742.00K -1.37B -1.07B -7.0731

Allogene Therapeutics Inc Stock (ALLO) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2026-04-16 アップグレード JP Morgan Underweight → Neutral
2026-04-10 再開されました Jefferies Buy
2026-01-09 アップグレード Citizens JMP Mkt Perform → Mkt Outperform
2025-10-10 ダウングレード JP Morgan Neutral → Underweight
2025-05-14 ダウングレード Citizens JMP Mkt Outperform → Mkt Perform
2025-03-14 アップグレード Citizens JMP Mkt Perform → Mkt Outperform
2024-08-08 再開されました Oppenheimer Outperform
2024-05-31 開始されました Piper Sandler Overweight
2024-01-05 ダウングレード Guggenheim Buy → Neutral
2024-01-05 ダウングレード JMP Securities Mkt Outperform → Mkt Perform
2023-12-08 開始されました Citigroup Buy
2023-06-26 再開されました Oppenheimer Outperform
2023-03-21 開始されました Bernstein Mkt Perform
2023-01-24 アップグレード JP Morgan Neutral → Overweight
2023-01-06 アップグレード Robert W. Baird Neutral → Outperform
2022-12-12 ダウングレード BofA Securities Buy → Underperform
2022-08-10 ダウングレード Raymond James Outperform → Mkt Perform
2022-07-15 アップグレード Goldman Neutral → Buy
2022-06-03 開始されました Robert W. Baird Neutral
2022-02-28 繰り返されました B. Riley Securities Buy
2021-10-20 開始されました Cowen Outperform
2021-10-08 ダウングレード Goldman Buy → Neutral
2021-10-08 ダウングレード Stifel Buy → Hold
2021-09-23 アップグレード Raymond James Mkt Perform → Outperform
2021-06-21 再開されました Jefferies Buy
2021-05-20 アップグレード Truist Hold → Buy
2021-05-14 開始されました B. Riley Securities Buy
2021-01-26 アップグレード Stifel Hold → Buy
2020-12-10 再開されました H.C. Wainwright Buy
2020-11-24 開始されました BofA Securities Buy
2020-10-23 開始されました RBC Capital Mkts Outperform
2020-06-01 ダウングレード Raymond James Outperform → Mkt Perform
2020-05-29 繰り返されました H.C. Wainwright Buy
2020-05-19 アップグレード ROTH Capital Neutral → Buy
2020-05-15 アップグレード Guggenheim Neutral → Buy
2020-05-14 繰り返されました H.C. Wainwright Buy
2020-05-14 ダウングレード SunTrust Buy → Hold
2020-04-13 開始されました SunTrust Buy
2020-03-13 開始されました H.C. Wainwright Buy
2020-03-05 開始されました Stifel Hold
2020-02-24 開始されました Berenberg Hold
2019-12-18 開始されました JMP Securities Mkt Outperform
2019-11-04 開始されました Canaccord Genuity Buy
2019-08-09 開始されました BTIG Research Buy
2019-06-05 開始されました ROTH Capital Neutral
2019-05-31 開始されました Guggenheim Neutral
2019-05-23 開始されました Stifel Hold
2019-03-29 開始されました Piper Jaffray Overweight
すべてを表示

Allogene Therapeutics Inc (ALLO) 最新ニュース

pulisher
Aug 21, 2026

Allogene (NASDAQ: ALLO) exec plans sale of 29,697 shares - Stock Titan

Aug 21, 2026
pulisher
Aug 21, 2026

Allogene Therapeutics, Inc. SEC Filing (Aug 21, 2026) - Stock Titan

Aug 21, 2026
pulisher
Aug 20, 2026

Allogene (ALLO) Earnings Report: The Bottom-Line Figure Outpaces Its Comparison in the Current Update; Stock Move: Shares Finish 5.83% Down in the Available RecordEarnings Season Outlook - Vinanet

Aug 20, 2026
pulisher
Aug 20, 2026

Allogene Therapeutics, Inc. (ALLO) Latest Stock News & Headlines - Yahoo Finance

Aug 20, 2026
pulisher
Aug 20, 2026

Allogene Therapeutics, Inc. (ALLO) Stock Price, News, Quote & History - Yahoo Finance

Aug 20, 2026
pulisher
Aug 20, 2026

Companies Like Allogene Therapeutics (NASDAQ:ALLO) Are In A Position To Invest In Growth - Moomoo

Aug 20, 2026
pulisher
Aug 19, 2026

Allogene (ALLO) Q2 2026 Earnings Call Transcript - Yahoo Finance

Aug 19, 2026
pulisher
Aug 18, 2026

Allogene Therapeutics (ALLO) Institutional Ownership 2026 $ALLO - MarketBeat

Aug 18, 2026
pulisher
Aug 17, 2026

symbol__ Stock Quote Price and Forecast - CNN

Aug 17, 2026
pulisher
Aug 17, 2026

ALLO Reiterated by Citizens -- Price Target Maintained at $6.00 - GuruFocus

Aug 17, 2026
pulisher
Aug 17, 2026

Is Allogene Therapeutics (ALLO) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance

Aug 17, 2026
pulisher
Aug 17, 2026

Citizens reiterates Allogene stock rating on trial progress By Investing.com - Investing.com Nigeria

Aug 17, 2026
pulisher
Aug 17, 2026

Citizens reiterates Allogene stock rating on trial progress - Investing.com

Aug 17, 2026
pulisher
Aug 15, 2026

Allogene Therapeutics (ALLO) Gains 3.54% as Shares Approach $2.15 ResistanceDemand Zone - vinanet.vn

Aug 15, 2026
pulisher
Aug 15, 2026

Walleye Capital LLC Invests $6.80 Million in Allogene Therapeutics, Inc. $ALLO - MarketBeat

Aug 15, 2026
pulisher
Aug 14, 2026

Allogene Therapeutics (ALLO): Frazier funds disclose 5.6% ownership and affiliated stakes - Stock Titan

Aug 14, 2026
pulisher
Aug 14, 2026

Allogene Therapeutics (ALLO) Income Statement & Earnings - Moomoo

Aug 14, 2026
pulisher
Aug 14, 2026

Clinical: FDA Accelerates Allogene's TALEN-Edited Lymphoma Cell Therapy - CRISPR Medicine News

Aug 14, 2026
pulisher
Aug 13, 2026

State Street Corp Expands Allogene Therapeutics (ALLO) Stake wit - GuruFocus

Aug 13, 2026
pulisher
Aug 13, 2026

Allogene Therapeutics' Q2 Earnings Beat Estimates on Lower R&D Costs - The Globe and Mail

Aug 13, 2026
pulisher
Aug 13, 2026

A Quick Look at Today's Ratings for Allogene Therapeutics(ALLO.US), With a Forecast Between $9 to $14 - Moomoo

Aug 13, 2026
pulisher
Aug 13, 2026

Piper Sandler Maintains Allogene Therapeutics(ALLO.US) With Buy Rating, Maintains Target Price $10 - Moomoo

Aug 13, 2026
pulisher
Aug 13, 2026

Allogene Therapeutics Remains Attractive Given Valuation, Clinical Strategy, RBC Says - marketscreener.com

Aug 13, 2026
pulisher
Aug 13, 2026

TD Cowen Maintains Allogene Therapeutics(ALLO.US) With Buy Rating - Moomoo

Aug 13, 2026
pulisher
Aug 13, 2026

Allogene Therapeutics, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance

Aug 13, 2026
pulisher
Aug 13, 2026

722,928 Shares in Allogene Therapeutics, Inc. $ALLO Acquired by Hennion & Walsh Asset Management Inc. - marketbeat.com

Aug 13, 2026
pulisher
Aug 13, 2026

Allogene Therapeutics earnings beat by $0.04, revenue topped estimates - Investing.com Canada

Aug 13, 2026
pulisher
Aug 13, 2026

Allogene Therapeutics Inc (ALLO) (Q2 2026) Earnings Call Highlights: RMAT Designation and Rapid ... - Yahoo Finance

Aug 13, 2026
pulisher
Aug 13, 2026

Allogene Therapeutics Inc (ALLO) (Q2 2026) Earnings Call Highlig - GuruFocus

Aug 13, 2026
pulisher
Aug 12, 2026

Allogene Therapeutics Inc (ALLO) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus

Aug 12, 2026
pulisher
Aug 12, 2026

Allogene Therapeutics (ALLO) Advances Clinical Pipeline Amidst H - GuruFocus

Aug 12, 2026
pulisher
Aug 12, 2026

Allogene Therapeutics: Q2 Earnings Snapshot - AOL.com

Aug 12, 2026
pulisher
Aug 12, 2026

Allogene Therapeutics Q2 2026: EPS beats, cash extends to 2029 - scanx.trade

Aug 12, 2026
pulisher
Aug 12, 2026

Transcript : Allogene Therapeutics, Inc., Q2 2026 Earnings Call, Aug 12, 2026 - marketscreener.com

Aug 12, 2026
pulisher
Aug 12, 2026

Allogene Therapeutics Announces Q2 2026 Financial Results Highlighting Reduced Losses, First Collaboration Revenue, and Significant Equity Raise - Kalkine Media

Aug 12, 2026
pulisher
Aug 12, 2026

Earnings call transcript: Allogene Therapeutics beats Q2 2026 EPS forecast By Investing.com - Investing.com Canada

Aug 12, 2026
pulisher
Aug 12, 2026

Allogene Therapeutics, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView

Aug 12, 2026
pulisher
Aug 12, 2026

Allogene Therapeutics Q2 Earnings Call Highlights - marketbeat.com

Aug 12, 2026
pulisher
Aug 12, 2026

Earnings call transcript: Allogene Therapeutics beats Q2 2026 EPS forecast - Investing.com

Aug 12, 2026
pulisher
Aug 12, 2026

Allogene TherapeuticsMay Offer Up To $500 Million In Securities - TradingView

Aug 12, 2026
pulisher
Aug 12, 2026

Allogene Therapeutics Q2 Loss Narrows - marketscreener.com

Aug 12, 2026
pulisher
Aug 12, 2026

Allogene Therapeutics (NASDAQ:ALLO) Issues Earnings Results, Beats Estimates By $0.04 EPS - MarketBeat

Aug 12, 2026
pulisher
Aug 12, 2026

Earnings Flash (ALLO) Allogene Therapeutics Posts Q2 Loss $0.13 per Share, vs. FactSet Est of $0.17 Loss - marketscreener.com

Aug 12, 2026
pulisher
Aug 12, 2026

Allogene posts $42.7 million Q2 loss as cash reaches $423.6 million - Quiver Quantitative

Aug 12, 2026
pulisher
Aug 12, 2026

Allogene Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com

Aug 12, 2026
pulisher
Aug 12, 2026

ALLO: ALPHA3 interim results highlight cema-cel's promise in LBCL and strong financial runway - tradingview.com

Aug 12, 2026
pulisher
Aug 12, 2026

Allogene Therapeutics, Inc. Announces Cemacabtagene Ansegedleucel (Cema-Cel) Is Being Evaluated in Alpha3, the First Pivotal, Randomized Phase 2 Trial in LBCL - marketscreener.com

Aug 12, 2026
pulisher
Aug 12, 2026

Allogene Therapeutics Reports Second Quarter 2026 Financial Results and Business Update - The Manila Times

Aug 12, 2026
pulisher
Aug 12, 2026

Allogene Therapeutics (ALLO) Edges Higher: CAR-T Developer Tests Key Resistance at $2.23Earnings Beat Stocks - Vinanet

Aug 12, 2026
pulisher
Aug 11, 2026

Allogene Therapeutics Inc (ALLO) Q2 2026 Earnings Report Preview: What To Look For - finance.yahoo.com

Aug 11, 2026
pulisher
Aug 10, 2026

Allogene Therapeutics, Inc. expected to post a loss of 17 cents a shareEarnings Preview - TradingView

Aug 10, 2026

Allogene Therapeutics Inc (ALLO) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$61.31
price up icon 1.21%
$125.77
price up icon 0.55%
$116.57
price up icon 5.12%
$236.22
price up icon 3.02%
ONC ONC
$374.47
price up icon 1.44%
$209.46
price down icon 1.07%
大文字化:     |  ボリューム (24 時間):